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Abstract
Background—Pooled viral load (VL) testing with two different testing strategies was evaluated 
as a potential cost-saving method to monitor antiretroviral therapy (ART) in HIV-infected children 
receiving ART in a resource-limited setting.
Methods—Archived samples collected from 250 HIV-1 infected children on first-line ART at 
various time-points post-ART initiation were evaluated for pooled VL testing using a minipool
+algorithm strategy. Additionally, samples collected in real-time from 125 children on ART were 
assessed for virologic failure using a minipool strategy for pooled viral load testing. Virologic 
failure was determined as HIV-1 RNA viral loads >1500 copies/ml.
Results—Minipool+algorithm strategy for pooled VL testing of archived samples had estimated 
viral failure of 13.6%, with a relative efficiency (RE) of 23.6% (95% CI; 18.5, 29.4), and negative 
predictive value (NPV) of 88%. This testing strategy would have resulted in 24% fewer assays 
needed, for a cost savings of $1,180 per 100 samples. The minipool strategy for pooled viral load 
testing of samples obtained in real-time yielded an estimated 23.2% of samples with viral failure 
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and a RE of 8.0 % (95% CI; 3.9, 14.2); however had a minipool+algorithm pooling strategy been 
used the RE would increase to 20%.
Conclusions—The minipool+algorithm strategy for pooled VL testing to detect virologic failure 
in HIV-1 infected children on ART was determined to be relatively efficient in detecting virologic 
failure, had high NPV, with substantial cost savings. Pooling strategies may be important 
components of cost-effect strategies to reduce rates of viral failure and resistance, thus improving 
clinical outcomes.
Introduction
Of the estimated 2.2 million HIV-1 infected children globally, over 90% reside in Africa. A 
global response to provide drug treatment has resulted in an unprecedented scale-up in the 
access to antiretroviral therapy (ART) in Africa. In Kenya approximately 24% of HIV-1 
infected children were receiving ART in 2010, most of whom were on first-line ARV 
therapy1. HIV-infected children have substantially higher viral loads than adults and 
consequently take longer to suppress after ART initiation2–6. Two recent separate meta-
analyses found that between 20% and 40% of children in Sub-Saharan Africa had 
incomplete viral suppression after 12 months on ART, which raises concerns regarding 
durability of first line ART regimens in children7, 8.
Current monitoring of response to ART in resource-limited settings is based on clinical and 
immunologic criteria and does not include viral load (VL) testing due to its high cost9–13. 
The WHO-based clinical and immunologic criteria for detecting virologic failure has low 
sensitivity: adult studies in developing countries have reported sensitivity rates of 12% – 
17%, and a recent pediatric study in Tanzania found a sensitivity rate of 3.5%14–18. A recent 
study in children on ARV therapy, aged between 24–84 months in South Africa found that 
virologic monitoring improved the sensitivity and predictive values for detecting virologic 
failure, compared to use of immunologic criteria alone19. A WHO survey in high HIV 
burden countries found 98% of children on first-line ART regimens with only 3% of 
children receiving second-line regimens20. The main reason for low usage of second-line 
regimens is failure to diagnose treatment failure promptly due to lack of regular virologic 
testing21.
Moreover, studies in resource-limited settings have reported high rates of drug resistance at 
the time of virologic failure3. Patients in programs that are not routinely monitored for VL 
had higher levels of resistance which compromise efficacy of currently recommended 
second-line regimens14, 15, 17. Among patients with faltering adherence, in addition to 
enhanced counseling, targeted VL testing may conserve first line ART by differentiating 
those with and without true virologic failure. Previous studies in adults have shown that 
targeted counseling in patients with detectable viral breakthrough resulted in a 3% to 5% 
drop in switching of patients to second line ART, thus promoting retention of first-line 
regimens10, 11. Infrequent monitoring of VL is commonly associated with delayed switch to 
second line ART regimens leading to accumulation of ARV resistance mutations and 
potential for poor outcomes of ART. A large multi-country study in adults found that use of 
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VL testing led to decisions to switch subjects to second-line treatment that are made earlier 
and at higher CD4 counts and may translate to better clinical outcomes16.
These factors highlight an urgent need to find cheaper technologies and strategies for VL 
testing and more cost-effective strategies for utilizing available technologies. While 
development of cheaper VL testing is desirable, progress to decrease VL test costs has been 
slow and unit cost of virologic testing remains about US $50 per test, which rules out the 
possibility of individual VL testing in many program settings.
Strategies of pooling specimens for testing were developed to decrease the cost of testing by 
reducing the number of tests required, and were initially used for detecting acute HIV 
infection among blood donors with a negative antibody test in areas where HIV prevalence 
is typically low (range 1% –30%)22–24. Several researchers have evaluated pooled sample 
viral testing strategies for detection of virologic failure in patients on ART. In studies 
conducted among populations of varying prevalence of ART failure, different cut-offs to 
define virologic failure have been evaluated25–27. These studies have shown that pooled VL 
testing can decrease the cost of virologic monitoring especially in populations with low 
prevalence of virologic failure25, 26. Strategies including minipool, minipool+algorithm and 
matrix have been described and evaluated to detect virologic failure using pooled samples25. 
Under these strategies, pools of individual samples are prepared for initial testing and 
compared against pre-defined viral detection thresholds; following viral detection above 
threshold of a given pool, varying approaches are then used to test individual samples.
The use of pooled VL testing of blood samples collected in real-time, to monitor ART 
failure, particularly from HIV-1 infected children on ART in low-resource settings have not 
been fully evaluated. This study describes the evaluation of minipool and minipool




Two source populations of HIV-1 infected children on ART were evaluated: (i) Archived 
samples collected previously from a research cohort of HIV-1 infected children on ART, 
and (ii) Real-time samples collected from HIV-1 infected children on ART in routine 
follow-up at the HIV clinic in the same hospital.
Archived Samples Cohort—The study used archived blood plasma specimens that were 
previously collected from HIV-1 infected children enrolled in an ongoing study on Long-
term Efficacy of Pediatric ART in Nairobi, which has been described previously6, 28, 29. 
Briefly, in this prospective, observational study HIV-1 infected children at Kenyatta 
National Hospital (KNH) were recruited between the years 2004 – 2006. Children aged 18 
months to 15 years were enrolled in the study if they presented with advance disease (WHO 
clinical stage 3–4) or CD4% <15%, and were ART naïve. Children were initiated on first-
line ARV regimens in tandem with National Guidelines: two nucleoside/nucleotide reverse 
transcriptase inhibitors (NRTIs) plus one non-nucleoside reverse transcriptase inhibitor 
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(NNRTI), except for those with pulmonary tuberculosis co-infection who were initiated on a 
regimen consisting of three drugs of the NRTI class. Following ART initiation, children 
were followed prospectively at monthly intervals during the first year and quarterly 
thereafter. At each clinic visit, information about medical illness and self-reported ART 
adherence was collected and complete physical examination including anthropometry was 
performed. Blood samples were collected at baseline and every 6 months thereafter to 
monitor immunologic response and drug toxicity. Response to ART was monitored using 
clinical (growth, opportunistic infection) and immunologic parameters.
Blood plasma samples were collected in duplicate: one sample was stored at −80°C while 
the other sample was previously tested for HIV-1 RNA VL using Gen-Probe HIV-1 Viral 
Load Assay (San Diego, CA), which has been validated for detection of HIV-1 subtypes 
prevalent in Kenya30. Stored frozen plasma were available for the present study for pooled 
VL testing, and 50 samples were selected at random from each of five time-intervals post-
ART initiation. The study received approval from the Kenyatta National Hospital and 
University of Washington IRB ethical review boards.
Real-time Samples Cohort—Plasma samples were obtained from HIV-infected children 
on ART enrolled in a PEPFAR-supported KNH treatment program in the same 
comprehensive HIV care clinic but not from participants in the previous study described 
above. Children were initiated on treatment between 2005 and 2011 according to the then 
existing Kenyan National Guidelines. Before 2007 the criteria was similar to that used for 
the archived samples (advanced disease (WHO clinical stage 3–4) or CD4% <15%) while 
after 2007 the national guidelines were adjusted to reflect age-specific CD4 criteria. Thus, 
for children < 5 years of age, CD4 percentage < 20% qualified for HAART initiation while 
those above 5 years of age the corresponding CD4 percentage threshold was 15%. 
Following ART initiation, children were monitored monthly for the first 6–12 months and 
quarterly thereafter. ART monitoring in the children was based on WHO-based clinical 
criteria (intercurrent illness, growth and development) and immunologic criteria (CD4 count 
and percentage). Prescriptions for ART were refilled every 1–3 months and information on 
adherence, toxicity and drug switches was recorded. HIV-1 RNA VL testing was not 
routinely done except for suspected treatment failure.
A total of 125 eligible children attending the clinic during the period between June and 
August 2011 were selected for pooled VL testing. Children initiated HAART between 
August 2005 and January 2011. A baseline venous blood sample was obtained from the 
child and he/she was given an appointment to return to the clinic after 2 weeks for VL 
results. If VL above 1500 copies/ml was detected (suggesting virologic failure), clinical and 
immunologic (e.g. CD4+ T cell count and percentage) assessments of failure were 
performed. For children with possible clinical, immunologic and virologic failure, a 
confirmation re-bleed sample for VL testing was requested. If the re-bleed sample had VL 
results above 1500 copies/ml, HIV viral resistance tests were performed to confirm 
treatment failure before switching to a second-line treatment.
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Approval of the present study was obtained from the KNH ethical review board. Informed 
consent for study participation was obtained from a parent or caregiver, and verbal assent 
was acquired for children above 8 years as per Kenya national guidelines.
Preparation of Pools for HIV-1 RNA VL Testing
Pools of either archived samples or samples obtained in real-time were prepared in the 
laboratory using 5 individual samples per pool (Figure 1). For the pools an approximate 
volume of 600 ul of pooled plasma was prepared, using 125 ul from each of the 5 individual 
samples. All pools and individual samples were coded and all staff involved in sample 
preparation or VL testing using pooled methods were blinded to the child’s previous VL 
results. Samples were tested for HIV-1 RNA VL using a commercial Abbot™ Real-Time 
HIV-1 Assay, which has a lower limit of detection of 50 copies/ml (and a standard deviation 
of 0.25). Virologic failure was defined as HIV-1 RNA greater than 1500 copies/ml.
Minipool+algorithm Strategy for Pooled VL Testing of Archived Samples
Pools of archived samples were prepared based on time of sample since ART initiation. 
Under a minipool+algorithm strategy if the VL result of the pool was less than 300 
copies/ml, then it was assumed that all five individual samples in the pool had VL ≤1500 
copies/ml (Figure 1). If the VL result of the pool was greater than 300 copies/ml, individual 
samples in the pool were tested sequentially; individual results (divided by the pool size) 
were subtracted from the pool VL estimate, until the threshold value was reached (≤300 
copies/ml). Hence, the remaining samples in the pool that had not been tested individually 
were assumed to be below the cut point defining virologic failure (<1500 copies/ml). One to 
two pools were prepared and tested per week. Implementation of this testing strategy 
required waiting for results from individual samples and depended on the number of 
individual samples tested; time for testing varied from 5 to 20 days.
Minipool strategy for Pooled VL Testing of Samples Obtained in Real-time
For testing of plasma samples obtained in real-time, the minipool strategy was evaluated 
because results were needed in real-time for monitoring of virologic failure and this strategy 
has a shorter turn-around time than the minipool+algorithm strategy.
Under this minipool strategy, if the VL result for the pool was <300 copies/ml then it was 
assumed that all individual samples had VL below 1500 copies/ml; while if the VL results of 
the pool were >300 copies/ml then all individual samples in the pool were tested (Figure 1). 
About one to two pools were prepared and tested per week, based on the volume of clinic 
attendance. Time for testing varied from 5 to 10 days.
Statistical Analysis
Relative Efficiency of Pooled VL Testing Strategies —Relative efficiency (RE) of 
each strategy was defined as one minus the number of assays performed divided by the 
number of samples25, and thus determines the percentage of assays saved by the pooling 
strategies compared with individual testing of all samples. A relative efficiency of zero has 
no advantage over individual testing while a relative efficiency of 50% uses half as many 
samples as individual testing. As reported by May et al25, an increased RE is function of 
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decreased prevalence of virologic failure in the population and the number of individual 
samples comprising a pool. Exact binomial 95% confidence intervals of relative efficiency 
were also calculated.
Negative Predictive Value of Pooled VL Testing Strategy—Negative predictive 
value (NPV) was calculated for the minipool+algorithm strategy for pooled testing of 
archived samples, as individual results were available from a previous analysis6. NPV 
represents the percentage of samples that truly do not have virologic failure under individual 
testing, among those samples determined to not have virologic failure by the pooling 
strategy. A high NPV indicates that most subjects determined to not have virologic failure 
by a testing strategy will be confirmed by individual testing.
All analyses were performed using Stata Intercooled v9.2 (College Station, StataCorp).
Results
Cohort Characteristics
Two hundred and fifty archived plasma samples were obtained from 100 children who 
participated in the Long-term Pediatric HAART efficacy cohort. At ART initiation children 
had a median age of 4.7 years (inter-quartile range (IQR), 2.7–6.6 years) and were initiated 
on first-line ART regimens (64 on nevirapine-containing regimens, 32 on efavirenz-
containing regimens, and 4 on triple NRTI regimens) (Table 1). Children had a median 
follow-up of 3 years (range 4–7 years). Archived blood samples collected within the 
following time intervals post ART initiation were available: 94 samples at 6 months, 86 
samples at 15 months, 85 samples at 27 months, 77 samples at 45 months and 55 samples at 
57 months. For the present study, 50 samples from each of the intervals were included, 
contributing a total of 250 samples collected from 100 children (Table 2). One sample was 
later determined to fall out of the desired range, and was excluded from examinations by 
time interval. Each child contributed a median of 3 samples (IQR, 2–3).
Samples obtained in real-time were collected from 125 children. Children had a median age 
of 5.9 years (IQR, 4.0 – 7.9 years) and were on the following ART regimens at the time of 
sample collection: 64 on nevirapine-containing regimens, 58 on efavirenz-containing 
regimens, 2 on ritonavir-boosted lopinavir containing regimens, and one on a triple NRTI 
regimen (Table 1). At the time of sample collection, children had been on ART between 4 
and 72 months: one child between 4–6 months, 24 between 6 months to one year, 33 
between 1–2 years, 23 between 2–3 years, 31 between 3–4 years, 9 between 4–5 years and 4 
between 5–6 years.
Relative Efficiency and Virologic Failure of Minipool+algorithm Strategy for Pooled VL 
Testing of Archived Samples
Overall, the minipool+algorithm strategy for pooled VL testing of archived samples had 
relative efficiency of 23.6% (95% CI, 18.5–29.4). A total of 34 (13.6%) of 250 samples 
were determined to have virologic failure (VL >1500 copies/ml). Relative efficiency was 
highest among samples collected either at 6 months, 1–2 years or 4–5 years post-ART, with 
relative efficiencies ≥30% (Table 2). Overall, 59 individual samples did not require 
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individual testing. Based on the current local cost of $50 per test, the program thus would 
have saved $2950 for the testing of 250 samples, or $1,180 per 100 tests.
Negative Predictive Value of Minipool+algorithm Strategy for Pooled VL Testing of 
Archived samples
Of the 216 archived samples determined to have VL <1500 copies/ml under a minipool
+algorithm strategy, 179 samples had individual results from a prior analysis. A total of 158 
samples were confirmed below threshold yielding overall NPV of 88% (95% CI, 83–93) 
(Table 3). Of the 21 samples that the strategy misclassified as VL < 1500 copies/ml, one 
sample was misclassified at the initial pool stage and 20 samples were misclassified at the 
individual, sequential testing stage.
Relative Efficiency and Virologic failure of Minipool Strategy for Pooled VL Testing of 
Samples Obtained in Real-time
For the minipool strategy for pooled VL testing of samples obtained in real time, overall 
relative efficiency was 8.0% (95% CI, 3.9–14.2) (Table 4). Ten samples did not have to be 
tested and thus the program would have saved only $500, or $400 per 100 tests. A total of 
29 (23.2%) of 125 children were found to have virologic failure (VL >1500 copies/ml). Of 
the 29 children, only 14 children met the additional clinical and/or immunologic criteria for 
classification of failure, and of those 9 were available for re-bleed and resistance testing; of 
these, 6 children were identified with ART resistant mutations indicating treatment failure.
Had the minipool+algorithm strategy been used for pooled VL testing of this samples 
obtained in real-time, estimated virologic failure would have decreased to 18.4% and RE 
would have increased to 20.0%.
Discussion
We analyzed pooled HIV-1 viral load testing using two strategies, the minipool and 
minipool+algorithm strategies, as has been described earlier25. We observed that pooled VL 
testing using a minipool+algorithm strategy was a more efficient and cost-saving strategy 
compared to use of a minipool strategy.
For archived samples using a minipool+algorithm strategy, we observed virologic failure of 
13.6% and relative efficiency of 23.6%. According to simulations done by May & others25, 
for a population with prevalence of virologic failure of about 13–14%, standard deviation of 
the assay of 0.12, and a minipool+algorithm strategy with pool size of 5, relative efficiency 
would be estimated at about 40–45%. However, use of an assay with standard deviation of 
0.25 like the Abbot™ Real-Time HIV-1 Assay used here may result in a somewhat lower 
RE, perhaps in the range of what we have observed. NPV was high at 88%, and cost savings 
would have been substantial at $1,180 per 100 tests.
We selected the minipool VL testing strategy to monitor virologic failure of samples in real-
time from children attending an ART clinic. We found the minipool testing strategy to have 
RE of 8% and not particularly cost-saving. However, had we subjected the same samples to 
a minipool+algorithm testing strategy relative efficiency would have increased to 20%. Thus 
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we observed that pooled VL testing using the minipool+algorithm was a more efficient and 
cost-saving strategy compared to minipool. It should be noted that due to the differing 
strategies of testing individual samples within pools that initially test above threshold, the 
minipool+algorithm may miss additional true positives that the minipool would not miss. In 
the archived samples cohort, all but one sample was missed at the individual, sequential 
testing stage. Further, in the samples obtained in real-time, the minipool strategy captured 6 
additional samples with virologic failure than did minipool+algorithm strategy; this would 
have contributed to the higher VF and lower RE seen. It is thus important that immunologic, 
growth, and other factors be examined to identify any samples with virologic failure that a 
testing strategy could miss.
To our knowledge this study is one of the first to perform pooled VL testing in a real-time, 
clinical management setting to confirm virologic failure in children in a resource-limited 
setting. In addition to evaluating a minipool+algorithm strategy, we also assessed a minipool 
testing strategy. While the minipool+algorithm testing strategy had higher relative 
efficiency, use of this strategy may lead to delay in VL results for individual samples in the 
pool. In a laboratory that performs VL testing on a routine basis, for example at least 3 days 
per week typical of a large busy lab, the minipool+algorithm strategy could be suitable as 
the turn-around time for testing is shorter and confirmatory VL results for an individual may 
be available within 2 to 3 weeks. However, in many smaller settings samples accrue more 
slowly, and a minipool testing strategy with shorter turnaround time may be more feasible.
Our study however did include a number of limitations. First, samples obtained in real-time 
were from children attending the clinic for ART monitoring, therefore samples were taken at 
varying lengths of time after ART initiation. Pooling and testing for VL according to time 
since ART initiation can be more efficient: time points with lower prevalences of virologic 
failure will yield more pools falling below the limit of detection, and thus require fewer tests 
of individual samples. However, this pooling of samples with varying times since ART 
initiation is likely to arise in smaller lab settings.
Second, for archived samples under the minipool+algorithm pooling strategy, samples from 
pool results above the threshold limit were tested individually using the Abbot™ Real-Time 
HIV-1 assay. However, individual results previously obtained in our collaborator’s 
laboratory and used to assess negative predictive value were tested using a Gen-Probe 
HIV-1 VL assay. Thus, the NPVs reported in our study represent both the shortcomings of a 
pooled VL testing strategy and use of different assays for viral load testing. Further, we 
could not calculate NPV of the minipool testing strategy used for samples obtained in real-
time. However, under a minipool testing strategy that tests all individual samples from 
positive pools, the source of undetected true positives arises only from pools that test below 
threshold.
Another limitation of our study is that we only used the minipool and minipool+algorithm 
strategies for pooled VL testing and there is a possibility that under certain conditions there 
may be other testing strategies that might be more efficient. A recent study conducted in 
adults on ART in a low-resource setting employed the matrix strategy, and found that with a 
prevalence 22% of virologic failure in the population the strategy was cost-effective and 
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saved more than 33% of the VL assays27. However, implementation of a matrix strategy is 
more complex and can increase the necessary technician time. Further exploration is needed 
in order to compare the performance of a matrix strategy to the strategies examined here.
In this study in children from a resource-limited setting, we demonstrated that pooled HIV-1 
RNA VL testing using the minipool+algorithm strategy to resolve positive pools, can reduce 
the cost of monitoring for virologic failure by up to a quarter compared with individual VL 
testing. This efficiency was demonstrated in our archived samples from pediatric HIV-1 
infected population with ~14% virologic failure, and was accompanied by a high negative 
predictive value. Moreover, while the minipool strategy for pooled VL testing is an 
appealing approach in real-time for clinical management, our study showed that use of 
minipool strategy was not efficient. Hence, with the use of pooled VL testing with a 
minipool+algorithm strategy and employment of low-cost technologies for VL assays, 
HIV-1 VL monitoring may become more accessible for low resource-settings. More 
research is needed to refine these methods toward achieving greater efficiency and 
simplicity.
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Strategy for pooled HIV-1 VL testing for all samples. The minipool and minipool+algorithm 
testing strategies have been previously described by May et al25.
*300 c/ml is the pool threshold of interest for pool size of 5 and definition of virologic 
failure as viral load > 1500 c/ml
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Table 1
Enrollment characteristics and ART regimens of children providing samples for pooled VL testing.








Age (years) 4.7 (2.7, 6.6) 5.9 (4.0, 7.9)
Male 56 (56) 75 (60)
Height (cm) 96 (83, 108) 111 (100, 121)
Weight (kg) 14 (10, 17) 19 (15, 22)
CD4%a 7 (4, 13) N/A
CD4 countb 352 (102, 659) 843 (470, 1167)
HIV-1 viral load (copies//ml)c 872,400 N/A
(287,900 – 2,822,300)
HAART regimen
   NVP/3TC/AZT 52 (52) 29 (23)
   NVP/3TC/ABC 0 27 (22)
   NVP/3TC/D4T 12 (12) 8 (6)
   EFV/3TC/AZT 23 (23) 26 (21)
   EFV/3TC/ABC 0 30 (24)
   EFV/3TC/D4T 9 (9) 2 (2)
   LPVr//3TC/AZT 0 1 (1)
   LPVr//3TC/ABC 0 1 (1)
   3TC/AZT/ABC 2 (2) 1 (1)
   3TC/D4T/ABC 1 (1) 0
   3TC/AZT/NFV 1 (1) 0
*
Children in the archived samples cohort were initiated on ART soon after enrollment, while children in the real-time samples cohort had been on 
ART for 4 to 72 months at the time of enrollment.
a
CD4% results were available from N=88 children in the archived samples cohort, and were not collected from children in the real-time samples 
cohort.
b
CD4 count results were available from N=86 children in the archived samples cohort, and for N=20 children in the real-time samples cohort.
c
HIV-1 VL results were available from N=88 children in the archived samples cohort, and were not collected from children in the real-time 
samples cohort.
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Table 3












Overall 216 179 158 88 (83–93)
6 month 43 41 39 95 (83–99)
1–2 years 44 41 37 90 (77–97)
2–3 years 42 33 28 85 (68–95)
3–4 years 43 30 25 83 (65–94)
4–5 years 43 34 29 85 (69–95)
*
Individual sample VL results were available from a prior study.
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